CTOs on the Move

Aldagen

www.aldagen.com

 
Aldagen is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aldagen.com
  • 2810 Meridian Pkwy Ste 148
    Durham, NC USA 27713
  • Phone: 919.484.2571

Executives

Name Title Contact Details

Similar Companies

UVJ technology

UVJ technology is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accelerated Technologies Partners

Accelerated Technologies Partners is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ology Bioservices

Ology Bioservices is a private, American biopharmaceutical company headquartered in Alachua, Florida.

Aduro Biotech

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro`s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro`s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.